市場調查報告書
商品編碼
670589

全球EPO生物標記市場與預測

Global EPO Biomarkers Market Research and Forecast 2018-2023

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球EPO生物標記市場相關調查,彙整市場現狀與成長預測,生物標記類別,各用途,各終端用戶,各地區趨勢,及加入此市場的主要企業的簡介等資料。

第1章 報告的摘要

第2章 市場概要與考察

  • 定義
  • 分析師的考察與市場的現狀
  • 法律規章

第3章 市場決策因素

  • 促進要素
  • 阻礙要素
  • 機會

第4章 市場區隔

  • 生物標記類別
    • 促血紅細胞生長素Alpha
    • 促血紅細胞生長素β
    • 促血紅細胞生長素ZETA
    • 促血紅細胞生長素THETA
    • 重組人體促血紅細胞生長素
    • DARBEPOIETIN ALFA
  • 各用途
    • 末期疾病
    • 癌症
    • 類風濕性關節炎
    • AIDS
    • 骨髓發育不良症候群
    • 神經
    • 血管
    • 其他
  • 各終端用戶
    • 診斷中心
    • 門診外科中心
    • 醫院

第5章 競爭環境

第6章 各地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第7章 企業簡介

目錄
Product Code: OMR2018354

Erythropoietin (EPO) is a hormone that is produced from the kidney inside the human body. EPO biomarkers Market are used to increase the growth of red blood cells in the body by stimulating the bone marrow. Some of the EPO biomarkers available in the market are epoetin alfa, epoetin beta, epoetin zeta, epoetin theta, recombinant human erythropoietin, and darbepoetin alfa. Erythropoietin alfa is used to treat anemia and cancer cells and it increases the count of red blood cells in the body. Erythropoietin is mostly administered as an alternative to iron supplements. Moreover, the erythropoietin biomarkers are used to treat end-stage renal diseases (ESRD), and anemia induced from multiple myeloma, cancer, and AIDS associated anemia.

Major factors contributing to the growth of the global EPO biomarkers market include increasing sedentary lifestyle and faulty dietary habits has increased the prevalence of cancers and chronic kidney diseases in the emerged economies. Moreover, the increasing incidence of end-stage renal disorders and hematological diseases is further increasing the demand for EPO biomarkers. The patent expiration of EPO biomarkers is significantly increasing the introduction of novel EPO biomarkers in the market. However, the lack of quality control testing laboratories in emerging economies such as India and China is a major factor hindering the growth of the market. Improper price capping regulations across the globe is another factor that is significantly responsible in hampering the growth of the global EPO biomarkers market. However, the favorable healthcare regulations in emerged economies such as the U.S. and rising prevalence of chronic diseases such as cancer is expected to fuel the market growth in the near future.

The EPO Biomarkers Market can be segmented on the basis of biomarker type, applications, and end users. Based on biomarker type, the market is segmented into erythropoietin alfa, erythropoietin beta, erythropoietin zeta, erythropoietin theta, recombinant human erythropoietin, and darbepoietin alfa. Based on application, the market is bifurcated into end-stage renal disorder, cancers, rheumatoid arthritis, AIDS, myelodysplastic syndrome, neurology, hematology, and others (anaemia of chronic inflammatory syndromes). Based on end users, the market is segmented into diagnostic centers, ambulatory care and surgical centers, and hospitals. Among biomarker type, the erythropoietin alfa segment holds a major share in the global EPO biomarkers market. This is owing to increasing adoption in the treatment of chronic renal disorders and cancer.

The global EPO biomarkers market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America holds a dominant position in the global EPO biomarkers market, followed by Europe. This is mainly owing to the developed healthcare infrastructure in the region. Moreover, the systematic initiatives taken by the government in the research and development activities is one of the major factors contributing in the growth of the EPO biomarkers market in the region. Asia Pacific is projected to exhibit the fastest growth in the global market over the forecast period. Some of the major factors that are significantly contributing in the growth of the market in Asia Pacific are low cost of treatment therapy and increasing incidence rate of hematological diseases in the region, especially in India, China, Pakistan, and Bangladesh.

Some of the key players operating in the global EPO biomarkers market are Siemens AG, Thermo Fisher Scientific, Pfizer Inc., Novartis AG, Johnson & Johnson Services, Inc., Merck KGaA, LG Lifesciences Pvt Ltd, Amgen Inc., F. Hoffmann-LA Roche Ltd, and Agilent Technologies, Inc., among others. In order to sustain in the competitive market, these players adopt various strategies such as acquisitions, mergers, expansions, joint ventures, and product development, among others. For instance, in January 9, 2017, the Amgen Inc. has signed an agreement with DaVita Inc., a US-based healthcare solution provider. According to the agreement, the Amgen Inc. will supply DaVita's EPOGEN (epoetin alfa) and Aranesp (darbepoetin alfa) in the U.S. and Puerto Rico.

Research Methodology

The market study of EPO biomarkers market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:

  • Financial reports of companies involved in the market
  • Authentic public databases such as WHO, World Anti-Doping Agency (WADA), and Centers for Disease Control and Prevention (CDC), among others.
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalogue
  • Supplier Websites such as Alibaba, amazon for pricing analysis

The report is intended for drug manufacturers, healthcare providers, private companies for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.

Market Segmentation:

Global EPO biomarkers market is segmented on the basis of regional outlook and following segments:

  • 1. Global EPO Biomarkers Market Research and Analysis, By Biomarker Type
  • 2. Global EPO Biomarkers Market Research and Analysis, By Applications
  • 3. Global EPO Biomarkers Market Research and Analysis, By End Users
  • 4. Global EPO Biomarkers Market Research and Analysis, By Region

THE REPORT COVERS:

  • Comprehensive research methodology of global EPO biomarkers market
  • This report also includes detailed and extensive market overview with key analyst insights
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations
  • Analysis of regional regulations and other government policies impacting the global EPO biomarkers market
  • Insights about market determinants which are stimulating the global EPO biomarkers market
  • Detailed and extensive market segments with regional distribution of forecasted revenues
  • Extensive profiles and recent developments of market players

Table of Contents

CHAPTER 1. REPORT SUMMARY

  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
    • 1.2.1. BY SEGMENTS
    • 1.2.2. BY GEOGRAPHY
    • 1.2.3. BY STAKEHOLDERS

CHAPTER 2. MARKET OVERVIEW AND INSIGHTS

  • 2.1. DEFINITION
  • 2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
    • 2.2.1. KEY FINDINGS
    • 2.2.2. RECOMMENDATION
    • 2.2.3. CONCLUSION
  • 2.3. REGULATIONS
      • 2.3.1.1. UNITED STATES
      • 2.3.1.2. EUROPEAN UNION
      • 2.3.1.3. CHINA
      • 2.3.1.4. INDIA

CHAPTER 3. MARKET DETERMINANT

  • 3.1. MOTIVATORS
    • 3.1.1. INCREASING INCIDENCE OF CANCERS AND RENAL DISORDERS
    • 3.1.2. SEDENTARY LIFESTYLE AND FAULTY DIETARY HABITS
    • 3.1.3. INCREASING PREVALENCE OF CHRONIC KIDNEY DISEASES SUCH AS DIABETES
    • 3.1.4. UPCOMING PATENT EXPIRATION OF EPO BIOMARKERS
  • 3.2. RESTRAINTS
    • 3.2.1. LESS OF QUALITY CONTROL TESTING LABORATORIES IN EMERGING ECONOMIES
  • 3.3. OPPORTUNITIES
    • 3.3.1. FAVORABLE HEALTHCARE REGULATIONS IN EMERGED ECONOMIES

CHAPTER 4. MARKET SEGMENTATION

  • 4.1. GLOBAL EPO BIOMARKER MARKET, BY BIOMARKER TYPE
    • 4.1.1. ERYTHROPOIETIN ALFA
    • 4.1.2. ERYTHROPOIETIN BETA
    • 4.1.3. ERYTHROPOIETIN ZETA
    • 4.1.4. ERYTHROPOIETIN THETA
    • 4.1.5. RECOMBINANT HUMAN ERYTHROPOIETIN
    • 4.1.6. DARBEPOIETIN ALFA
  • 4.2. GLOBAL EPO BIOMARKER MARKET, BY APPLICATIONS
    • 4.2.1. END-STAGE RENAL DISORDER
    • 4.2.2. CANCERS
    • 4.2.3. RHEUMATOID ARTHRITIS
    • 4.2.4. AIDS
    • 4.2.5. MYELODYSPLASTIC SYNDROME
    • 4.2.6. NEUROLOGY
    • 4.2.7. HEMATOLOGY
    • 4.2.8. OTHERS (ANAEMIA OF CHRONIC INFLAMMATORY SYNDROMES)
  • 4.3. GLOBAL EPO BIOMARKER MARKET, BY END USERS
    • 4.3.1. DIAGNOSTIC CENTERS
    • 4.3.2. AMBULATORY CARE AND SURGICAL CENTERS
    • 4.3.3. HOSPITALS

CHAPTER 5. COMPETITIVE LANDSCAPE

CHAPTER 6. REGIONAL ANALYSIS

  • 6.1. NORTH AMERICAN
    • 6.1.1. UNITED STATES
    • 6.1.2. CANADA
  • 6.2. EUROPE
    • 6.2.1. U.K
    • 6.2.2. GERMANY
    • 6.2.3. ITALY
    • 6.2.4. SPAIN
    • 6.2.5. FRANCE
    • 6.2.6. ROE
  • 6.3. ASIA PACIFIC
    • 6.3.1. INDIA
    • 6.3.2. CHINA
    • 6.3.3. JAPAN
    • 6.3.4. ROAPAC
  • 6.4. REST OF THE WORLD

CHAPTER 7. COMPANY PROFILES

  • 7.1. 3SBIO GROUP
  • 7.2. AGILENT TECHNOLOGIES, INC.
  • 7.3. AMGEN INC.
  • 7.4. BIOAGILYTIX LABS
  • 7.5. BIOCON
  • 7.6. BIO-RAD LABORATORIES, INC.
  • 7.7. EVE TECHNOLOGIES
  • 7.8. F. HOFFMANN-LA ROCHE LTD
  • 7.9. GALENICA AG
  • 7.10. GENSCRIPT
  • 7.11. GLAXOSMITHKLINE PLC.
  • 7.12. INTAS PHARMACEUTICALS LTD.
  • 7.13. JOHNSON & JOHNSON SERVICES, INC.
  • 7.14. KYOWA HAKKO KIRIN CO., LTD.
  • 7.15. LG LIFESCIENCES PVT LTD
  • 7.16. MERCK KGAA
  • 7.17. MYRIAD RBM
  • 7.18. NOVARTIS AG
  • 7.19. PACIFIC BIOMARKERS
  • 7.20. PFIZER INC.
  • 7.21. SANDOZ INTERNATIONAL GMBH
  • 7.22. SHANDONG KEXING
  • 7.23. SIEMENS AG
  • 7.24. THERMO FISHER SCIENTIFIC

List of Tables

  • TABLE # 1 GLOBAL EPO BIOMARKER MARKET RESEARCH AND ANALYSIS, BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
  • TABLE # 2 GLOBAL ERYTHROPOIETIN ALFA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 3 GLOBAL ERYTHROPOIETIN BETA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 4 GLOBAL ERYTHROPOIETIN ZETA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 5 GLOBAL ERYTHROPOIETIN THETA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 6 GLOBAL RECOMBINANT HUMAN ERYTHROPOIETIN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 7 GLOBAL DARBEPOIETIN ALFA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 8 GLOBAL EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
  • TABLE # 9 GLOBAL END-STAGE RENAL DISORDER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 10 GLOBAL CANCERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 11 GLOBAL RHEUMATOID ARTHRITIS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 12 GLOBAL AIDS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 13 GLOBAL MYELODYSPLASTIC SYNDROME MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 14 GLOBAL NEUROLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 15 GLOBAL HEMATOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 16 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 17 GLOBAL EPO BIOMARKER MARKET RESEARCH AND ANALYSIS, BY END USERS, 2017-2023 ($ MILLION)
  • TABLE # 18 GLOBAL DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 19 GLOBAL AMBULATORY CARE AND SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 20 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 21 GLOBAL EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
  • TABLE # 22 NORTH AMERICAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 23 NORTH AMERICAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
  • TABLE # 24 NORTH AMERICAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
  • TABLE # 25 NORTH AMERICAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
  • TABLE # 26 EUROPEAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 27 EUROPEAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
  • TABLE # 28 EUROPEAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
  • TABLE # 29 EUROPEAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
  • TABLE # 30 APAC EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 31 APAC EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
  • TABLE # 32 APAC EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
  • TABLE # 33 APAC EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
  • TABLE # 34 ROW EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
  • TABLE # 35 ROW EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
  • TABLE # 36 ROW EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL EPO BIOMARKER MARKET SHARE BY BIOMARKER TYPE, 2017 VS 2023 (%)
  • FIGURE # 2 GLOBAL EPO BIOMARKER MARKET SHARE BY APPLICATIONS, 2017 VS 2023 (%)
  • FIGURE # 3 GLOBAL EPO BIOMARKER MARKET SHARE BY END USERS, 2017 VS 2023 (%)
  • FIGURE # 4 US EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 5 CANADA EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 6 UK EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 7 FRANCE EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 8 GERMANY EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 9 ITALY EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 10 SPAIN EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 11 ROE EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 12 INDIA EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 13 CHINA EPO BIOMARKER MARKETSIZE, 2017-2023 ($ MILLION)
  • FIGURE # 14 JAPAN EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 15 ROAPAC EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 16 REST OF THE WORLD EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)